United Therapeutics Corp (UTHR)
233.75
-2.20
(-0.93%)
USD |
NASDAQ |
Apr 26, 16:00
233.75
0.00 (0.00%)
After-Hours: 19:06
United Therapeutics Revenue (Quarterly): 614.70M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 614.70M |
| September 30, 2023 | 609.40M |
| June 30, 2023 | 596.50M |
| March 31, 2023 | 506.90M |
| December 31, 2022 | 491.50M |
| September 30, 2022 | 516.00M |
| June 30, 2022 | 466.90M |
| March 31, 2022 | 461.90M |
| December 31, 2021 | 415.20M |
| September 30, 2021 | 444.70M |
| June 30, 2021 | 446.50M |
| March 31, 2021 | 379.10M |
| December 31, 2020 | 384.90M |
| September 30, 2020 | 380.10M |
| June 30, 2020 | 362.00M |
| March 31, 2020 | 356.30M |
| December 31, 2019 | 311.10M |
| September 30, 2019 | 401.50M |
| June 30, 2019 | 373.60M |
| March 31, 2019 | 362.60M |
| December 31, 2018 | 381.40M |
| September 30, 2018 | 412.70M |
| June 30, 2018 | 444.50M |
| March 31, 2018 | 389.20M |
| December 31, 2017 | 464.70M |
| Date | Value |
|---|---|
| September 30, 2017 | 445.50M |
| June 30, 2017 | 444.60M |
| March 31, 2017 | 370.50M |
| December 31, 2016 | 409.00M |
| September 30, 2016 | 408.20M |
| June 30, 2016 | 412.60M |
| March 31, 2016 | 369.00M |
| December 31, 2015 | 404.90M |
| September 30, 2015 | 386.20M |
| June 30, 2015 | 347.20M |
| March 31, 2015 | 327.50M |
| December 31, 2014 | 346.34M |
| September 30, 2014 | 329.95M |
| June 30, 2014 | 322.80M |
| March 31, 2014 | 289.40M |
| December 31, 2013 | 289.02M |
| September 30, 2013 | 302.22M |
| June 30, 2013 | 280.61M |
| March 31, 2013 | 245.14M |
| December 31, 2012 | 243.82M |
| September 30, 2012 | 242.47M |
| June 30, 2012 | 225.58M |
| March 31, 2012 | 204.21M |
| December 31, 2011 | 195.18M |
| September 30, 2011 | 201.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
311.10M
Minimum
Dec 2019
614.70M
Maximum
Dec 2023
448.36M
Average
444.70M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Liquidia Corp | 4.531M |
| Esperion Therapeutics Inc | 32.25M |
| Vertex Pharmaceuticals Inc | 2.518B |
| Heron Therapeutics Inc | 34.23M |
| Aldeyra Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 217.10M |
| Total Expenses (Quarterly) | 354.60M |
| EPS Diluted (Quarterly) | 4.36 |
| Enterprise Value | 8.809B |
| Gross Profit Margin (Quarterly) | 88.45% |
| Profit Margin (Quarterly) | 35.32% |
| Earnings Yield | 8.49% |
| Operating Earnings Yield | 10.20% |
| Normalized Earnings Yield | 8.488 |